CI Stock Analysis: Buy, Sell, or Hold?
CI - The Cigna Group
$277.51
3.10 (1.13%)
â˛
5d:
-1.79%
30d:
-3.07%
90d:
-1.6%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When CI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CI is fairly priced but lacks strong directional signals. At -1.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CI is fairly priced but lacks strong directional signals. At -1.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$400.58
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$248.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CI is currently trading at $277.51, which is considered slightly low relative to its 30-day fair value range of $274.90 to $293.04. The stock's valuation (Forward PE: 8.3) is in line with its historical norms (8.6). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 10.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CI is in a downtrend. The price is currently testing key support at $270.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CI scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $341.42 (+23.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CI is in a downtrend. The price is currently testing key support at $270.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CI scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $341.42 (+23.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$274.90 -
$293.04
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding CI? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.0% below Wall St target ($341.42)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$274.90 -
$293.04
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$270.91
Resistance Level
$285.74
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.29
Wall Street Target
$341.42
(+23.0%)
Revenue Growth (YoY)
6.7%
Earnings Growth (YoY)
10.2%
Profit Margin
2.3%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
8.3 vs 8.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$274.46
(-1%)
2-Year Target
$271.44
(-2%)
3-Year Target
$268.45
(-3%)
3-Yr Target (if PE normalizes)
(PE: 8â9)
$278.48
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 9.7%)
$887.46
(+220%)
Base:
(SPY PE: 8.3, Growth: 9.7%)
$366.59
(+32%)
Bear:
(PE: 7.0, Growth: 9.7%)
$311.60
(+12%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 11.47 | Current EPS (TTM): $23.93
Bull Case
$422.23
(+52%)
Analyst growth 39.9%, PE expands to 12.6
Base Case
$383.85
(+38%)
Market implied 39.9%, PE stable at 11.5
Bear Case
$186.60
(-33%)
Severe decline -20.0%, PE contracts to 9.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.3 to 8.6
Stabilization Target:
$287.87
(+3.7%)
PE Expansion Potential:
+3.7%
Share & Embed Analysis
Last updated: August 23, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Everett Neville
SELL
1719 shares
2026-03-02
Nicole S Jones
SELL
2307 shares
2026-03-02
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$116 | 65 BUY |
|
UNH
UnitedHealth Group IncorâĻ |
STRONG BUY
27 analysts |
$475 | 50 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$449 | 54 HOLD |
|
HUM
Humana Inc |
HOLD
26 analysts |
$416 | 60 BUY |
|
CNC
Centene Corp |
BUY
19 analysts |
$72 | 41 HOLD |
Advanced CI Option Strategies
Professional options setups generated by AI based on today's CI price and gamma walls.
